This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Cagrilintide (10 mg Vial)
Cagrilintide is a long-acting acylated analogue of the pancreatic hormone amylin[1]. It activates central amylin receptors to promote satiety, slow gastric emptying, and reduce food intake[2][3]. In phase 2 and phase 3 trials, cagrilintide produced dose-dependent weight loss with a predominantly gastrointestinal side-effect profile[4][5].
Quick Reference
What is Cagrilintide?
Research overview based on the cited scientific literature.
• Goal: Support satiety, reduce food intake, and promote weight management over time[2][4].
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw cycles.
Storage Instructions
Proper storage preserves peptide integrity and potency.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days and avoid freeze–thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is Cagrilintide studied?
Cagrilintide is an acylated, long-acting analogue of amylin—a hormone co-secreted with insulin from pancreatic beta cells[2][7]. Native amylin promotes satiation, slows gastric emptying, and inhibits postprandial glucagon secretion[8][9]. By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake[3][10]. Lipid modifications extend its half-life to approximately 160–195 hours, enabling once-weekly dosing[6][11].
What does the research report about Cagrilintide?
Observations from phase 2 and phase 3 clinical trials.
• Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo[4].
• Combination therapy: When combined with semaglutide 2.4 mg (CagriSema), phase 3 REDEFINE trials showed approximately 20% weight loss at 68 weeks, exceeding results with either agent alone[5][12].
• Dose-dependent efficacy: Higher doses (2.4–4.5 mg) demonstrate greater weight loss than lower doses (0.3–1.2 mg)[4].
• Side effects: Primarily gastrointestinal—nausea, vomiting, diarrhea, and constipation—which are generally mild-to-moderate and transient[4][5]. Gradual titration helps minimize these effects.
• Injection-site reactions: Occasional mild redness or irritation at subcutaneous injection sites.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on Cagrilintide?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.